ENG/中
老虎證券
行情
产品介绍
Cash Boost账户
美股
美股碎股
港股
A股通
期权
期货
美国国债
定投
固定票息票据
Tiger BOSS Debit Card
基金超市
老虎钱袋子
老虎API平台
Wealth
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
专栏
TigerAI
机构
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務
Inotek Pharmaceuticals Corporation
3.04
+0.0000
成交量:
- -
成交額:
- -
市值:
8,211.04萬
市盈率:
-1.99
高:
3.04
開:
3.04
低:
3.04
收:
3.04
資料載入中...
總覽
公司
新聞
公告
公司資料
公司名字:
Inotek Pharmaceuticals Corporation
交易所:
NASDAQ
成立時間:
- -
員工人數:
- -
公司地址:
- -
官網:
http://www.inotekpharma.com
郵編:
- -
電話:
- -
傳真:
- -
簡介:
Inotek製藥公司是於1999年7月7日根據美國特拉華州法律成立。該公司是一家臨床階段的生物製藥公司,專註於治療青光眼藥物的發現,開發和商業化。該公司領先的候選產品,trabodenoson,是一級可選擇的腺苷模擬,腺苷模擬是該公司通過恢複眼睛的自然壓力控制機制來降低眼壓機制。
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/ITEK/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ITEK","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ITEK\",,,,,undefined,":{"symbol":"ITEK","market":"US","secType":"STK","nameCN":"Inotek Pharmaceuticals Corporation","latestPrice":3.04,"timestamp":1515099600000,"preClose":3.04,"halted":4,"volume":0,"delay":0,"floatShares":12060000,"shares":27010000,"eps":-1.53,"marketStatus":"退市","change":0,"latestTime":"04-29 13:21:38 EDT","open":3.04,"high":3.04,"low":3.04,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.53,"tradingStatus":0,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1745956800000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":3.04,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ITEK\",,,,,undefined,":{"symbol":"ITEK","floatShares":12060000,"roa":"--","roe":"--","lyrEps":0,"shares":27010000,"dividePrice":0,"high":3.04,"amplitude":0,"preClose":3.04,"low":3.04,"week52Low":0.85,"pbRate":"1.43","week52High":3.8,"institutionHeld":0,"latestPrice":3.04,"eps":-1.53,"divideRate":0,"volume":0,"delay":0,"ttmEps":-1.53,"open":3.04},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.inotekpharma.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0719},{"period":"1month","weight":-0.0087},{"period":"3month","weight":-0.0888},{"period":"6month","weight":-0.0503},{"period":"1year","weight":0.0838},{"period":"ytd","weight":-0.0601}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Inotek製藥公司是於1999年7月7日根據美國特拉華州法律成立。該公司是一家臨床階段的生物製藥公司,專註於治療青光眼藥物的發現,開發和商業化。該公司領先的候選產品,trabodenoson,是一級可選擇的腺苷模擬,腺苷模擬是該公司通過恢複眼睛的自然壓力控制機制來降低眼壓機制。","exchange":"NASDAQ","name":"Inotek Pharmaceuticals Corporation","nameEN":"Inotek Pharmaceuticals"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"ITEK\",market:\"US\",,,undefined,":null,"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ITEK\",params:#limit:5,,,undefined,":[{"date":"2018-01-05","symbol":"ITEK","newSymbol":"RCKT","type":"symbolChange","dateTimestamp":1515128400000},{"market":"US","date":"2017-12-27","symbol":"ITEK","name":"Inotek Pharmaceuticals Corporation","time":"","type":"earning","dateTimestamp":1514350800000,"reportTimeType":""},{"market":"US","date":"2017-08-03","symbol":"ITEK","fiscalQuarterEnding":"2017/06","expectedEps":-0.54,"name":null,"time":"","type":"earning","dateTimestamp":1501732800000,"reportTimeType":"","actualEps":-0.24},{"market":"US","date":"2017-05-10","symbol":"ITEK","fiscalQuarterEnding":"2017/03","expectedEps":-0.35,"name":null,"time":"","type":"earning","dateTimestamp":1494388800000,"reportTimeType":"","actualEps":-0.4},{"market":"US","date":"2017-03-16","symbol":"ITEK","fiscalQuarterEnding":"2016/12","expectedEps":-0.39,"name":null,"time":"","type":"earning","dateTimestamp":1489636800000,"reportTimeType":"","actualEps":-0.48}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ITEK\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ITEK\",market:\"US\",delay:false,,,undefined,":{}}}